28 research outputs found
A Standardised Procedure for Evaluating Creative Systems: Computational Creativity Evaluation Based on What it is to be Creative
Computational creativity is a flourishing research area, with a variety of creative systems being produced and developed. Creativity evaluation has not kept pace with system development with an evident lack of systematic evaluation of the creativity of these systems in the literature. This is partially due to difficulties in defining what it means for a computer to be creative; indeed, there is no consensus on this for human creativity, let alone its computational equivalent. This paper proposes a Standardised Procedure for Evaluating Creative Systems (SPECS). SPECS is a three-step process: stating what it means for a particular computational system to be creative, deriving and performing tests based on these statements. To assist this process, the paper offers a collection of key components of creativity, identified empirically from discussions of human and computational creativity. Using this approach, the SPECS methodology is demonstrated through a comparative case study evaluating computational creativity systems that improvise music
ĐОНиПОŃŃиСП гона Ń ĐľĐźĐžĐşĐ¸Đ˝ĐžĐ˛ĐžĐłĐž ŃĐľŃопŃĐžŃĐ° CCR5 Ń ĐąĐžĐťŃĐ˝ŃŃ ŃĐ°ŃŃĐľŃннŃĐź ŃкНоŃОСОП в ХийиŃŃкОП ŃогиОно
Multiple sclerosis is chronic inflammatory disease of the central nervous system in the development of which chemokines of the type Tx1 play the leading role. Chemokines and their receptors participate in the development of multiple sclerosis as a result of drawing immune cells into central nervous system. Mutation of CCR5 delta32 decreases functional activity of the appropriate receptor on cellular surface and thus can reduce migration of leucocytes into foci of injury. Aimed at studying the role of mutation in multiple sclerosis, we compared frequency of gene type CCR5 in peripheral mononuclears of 102 multiple sclerosis patients and in 136 healthy subjects. The results obtained allow to conclude that polymorphism of chemokine receptor gene CCR5del32 is not a leading factor in the susceptibility to multiple sclerosis in the studied population.Đ Đ°ŃŃĐľŃннŃĐš ŃкНоŃОС (Đ ĐĄ) â Ń
ŃОниŃĐľŃкОо вОŃпаНиŃоНŃнОо СайОНованио ŃонŃŃĐ°ĐťŃнОК ноŃвнŃĐš ŃиŃŃоПŃ, в ŃаСвиŃии кОŃĐžŃОгО водŃŃоо СнаŃонио иПоŃŃ Đ˘Ń
1 Ńипа. ĐĽĐľĐźĐžĐşĐ¸Đ˝Ń Đ¸ иŃ
ŃĐľŃопŃĐžŃŃ ŃŃĐ°ŃŃвŃŃŃ Đ˛ ŃаСвиŃии Đ ĐĄ вŃНодŃŃвио ĐżŃивНоŃĐľĐ˝Đ¸Ń Đ¸ĐźĐźŃннŃŃ
кНоŃОк в ŃонŃŃĐ°ĐťŃĐ˝ŃŃ Đ˝ĐľŃвнŃŃ ŃиŃŃоПŃ. ĐŃŃĐ°ŃĐ¸Ń CCR5 delta32 ŃПонŃŃĐ°ĐľŃ ŃŃнкŃиОнаНŃĐ˝ŃŃ Đ°ĐşŃивнОŃŃŃ ŃООŃвоŃŃŃвŃŃŃогО ŃĐľŃопŃĐžŃĐ° на кНоŃĐžŃнОК пОвоŃŃ
нОŃŃи и ŃоП ŃĐ°ĐźŃĐź ĐźĐžĐśĐľŃ ŃодŃŃиŃОваŃŃ ĐźĐ¸ĐłŃĐ°ŃĐ¸Ń ĐťĐľĐšĐşĐžŃиŃОв в ĐžŃаги пОŃаМониŃ. ĐĄ ŃоНŃŃ Đ¸ĐˇŃŃĐľĐ˝Đ¸Ń ŃОНи ĐźŃŃĐ°Ńии ĐżŃи Đ ĐĄ ŃŃавниНаŃŃ ŃĐ°ŃŃĐžŃĐ° гонОŃипа CCR5 в поŃиŃĐľŃиŃĐľŃкиŃ
ПОнОнŃкНоаŃĐ°Ń
102 йОНŃĐ˝ŃŃ
Đ ĐĄ и 136 СдОŃОвŃŃ
НиŃ. ĐОНŃŃоннŃĐľ ŃоСŃĐťŃŃĐ°ŃŃ ĐżĐžĐˇĐ˛ĐžĐťŃŃŃ ĐˇĐ°ĐşĐťŃŃиŃŃ, ŃŃĐž пОНиПОŃŃиСП гона Ń
оПОкинОвОгО ŃĐľŃопŃĐžŃĐ° CCR5del32 но ŃвНŃĐľŃŃŃ Đ˛ĐľĐ´ŃŃиП ŃĐ°ĐşŃĐžŃОП в вОŃĐżŃииПŃивОŃŃи Đş ŃĐ°ŃŃĐľŃĐ˝Đ˝ĐžĐźŃ ŃкНоŃĐžĐˇŃ Đ˛ иСŃŃоннОК пОпŃĐťŃŃии
ĐОнОŃĐľŃĐ°ĐżĐ¸Ń Đ˝Đ¸Đ˛ĐžĐťŃПайОП Ń ĐąĐžĐťŃĐ˝ŃŃ ĐźĐľŃĐ°ŃŃĐ°ŃиŃĐľŃкиП кОНОŃокŃĐ°ĐťŃĐ˝ŃĐź ŃакОП: ŃОвŃоПоннŃĐľ ĐżĐžĐ´Ń ĐžĐ´Ń Đş ĐžŃонко ĐžŃвоŃĐ° ОпŃŃ ĐžĐťĐ¸
Aim of the study: a systematic analysis of the modern literature data on the nivolumab monotherapy efficacy in patients with metastatic colorectal cancer (mCRC). Material and methods. The review summarizes the results of clinical studies of the nivolumab efficacy in patients with mCRC between 2012 and 2022. The current approaches to assessing the tumor response in patients treated with immune checkpoint inhibitors are considered, including response patterns and criteria. Results. Data analysis showed that the use of nivolumab in mCRC patients had significant clinical benefits. Nivolumab monotherapy was shown to improve survival in patients with high microsatellite instability (MSI) or deficiencies in mismatch repair (dMMR) that progressed during standard chemotherapy. Numerous clinical studies indicate the atypical response to nivolumab. Traditional response criteria, such as RECIST do not always adequately assess the therapeutic efficacy of nivolumab in patients with mCRC. Conclusion. To improve the efficacy of mCRC treatment, standardized approaches based on the proposed specific criteria for response to immunotherapy, including immune related RECIST, immune RECIST, and immune-modified RECIST must be developed.ĐŚĐľĐťŃ Đ¸ŃŃĐťĐľĐ´ĐžĐ˛Đ°Đ˝Đ¸Ń â ŃиŃŃоПаŃиŃĐľŃкиК анаНиС даннŃŃ
ŃОвŃоПоннОК НиŃĐľŃĐ°ŃŃŃŃ ĐžĐą ŃŃŃокŃивнОŃŃи ĐżŃĐ¸ĐźĐľĐ˝ĐľĐ˝Đ¸Ń Đ˝Đ¸Đ˛ĐžĐťŃПайа в ПОнОŃоМиПо Ń ĐąĐžĐťŃĐ˝ŃŃ
ПоŃĐ°ŃŃĐ°ŃиŃĐľŃкиП кОНОŃокŃĐ°ĐťŃĐ˝ŃĐź ŃакОП (ĐźĐĐ Đ ). ĐĐ°ŃĐľŃиаН и ПоŃОдŃ. Đ ĐžĐąĐˇĐžŃ Đ˛ĐşĐťŃŃĐľĐ˝Ń Đ´Đ°Đ˝Đ˝ŃĐľ кНиниŃĐľŃкиŃ
иŃŃНодОваниК Са поŃиОд Ń 2012 пО 2022 Đł., ĐžŃониваŃŃиŃ
ŃŃŃокŃивнОŃŃŃ ĐťĐľŃĐľĐ˝Đ¸Ń Đ˝Đ¸Đ˛ĐžĐťŃПайОП Ń ĐąĐžĐťŃĐ˝ŃŃ
ĐźĐĐ Đ . Đ Đ°ŃŃПОŃŃĐľĐ˝Ń ŃокŃŃио пОдŃ
ĐžĐ´Ń Đş ĐžŃонко ОпŃŃ
ОНовОгО ĐžŃвоŃĐ°, вкНŃŃĐ°Ń Ń
Đ°ŃĐ°ĐşŃĐľŃ Đ¸ĐźĐźŃннОгО ĐžŃвоŃĐ° и ĐşŃиŃĐľŃии ĐžŃвоŃĐ°. РоСŃĐťŃŃĐ°ŃŃ. ĐнаНиС НиŃĐľŃĐ°ŃŃŃŃ ĐżĐžĐşĐ°ĐˇĐ°Đť, ŃŃĐž ĐżŃиПононио нивОНŃПайа ĐżŃи ĐźĐĐ Đ Đ¸ĐźĐľĐľŃ ĐˇĐ˝Đ°ŃиПŃĐľ кНиниŃĐľŃкио ĐżŃоиПŃŃĐľŃŃва. ĐŃОдоПОнŃŃŃиŃОванО, ŃŃĐž ПОнОŃĐľŃĐ°ĐżĐ¸Ń Đ˝Đ¸Đ˛ĐžĐťŃПайОП ŃĐťŃŃŃĐ°ĐľŃ ĐżĐžĐşĐ°ĐˇĐ°ŃоНи вŃМиваоПОŃŃи Ń ĐżĐ°ŃионŃОв Ń Đ˛ŃŃОкОК ПикŃĐžŃĐ°ŃоННиŃнОК ноŃŃайиНŃнОŃŃŃŃ (MSI) иНи наŃŃŃониоП ПоŃ
аниСПа ŃопаŃĐ°Ńии ноŃпаŃоннŃŃ
ĐžŃнОваниК ĐĐĐ (dMMR), кОŃĐžŃŃĐľ ĐżŃОгŃĐľŃŃиŃОваНи на ŃОно ŃŃандаŃŃнОК Ń
иПиОŃĐľŃапии. ĐнОгОŃиŃНоннŃĐľ кНиниŃĐľŃкио иŃŃĐťĐľĐ´ĐžĐ˛Đ°Đ˝Đ¸Ń ŃкаСŃваŃŃ Đ˝Đ° ŃаСвиŃио Đ°ŃипиŃĐ˝ŃŃ
ŃоакŃиК ĐžŃвоŃĐ° на нивОНŃПай. ТŃадиŃиОннŃĐľ ĐşŃиŃĐľŃии ĐžŃвоŃĐ°, Ńакио как RECIST, но вŃогда адокваŃнО ĐžŃониваŃŃ ŃĐľŃаповŃиŃĐľŃĐşŃŃ ŃŃŃокŃивнОŃŃŃ Đ˝Đ¸Đ˛ĐžĐťŃПайа Ń ĐżĐ°ŃионŃОв Ń ĐźĐĐ Đ . ĐакНŃŃонио. ĐĐťŃ ĐżĐžĐ˛ŃŃĐľĐ˝Đ¸Ń ŃŃŃокŃивнОŃŃи НоŃĐľĐ˝Đ¸Ń ĐźĐРРноОйŃ
ОдиПа ŃаСŃайОŃка ŃŃандаŃŃиСиŃОваннŃŃ
пОдŃ
ОдОв, ĐžŃнОваннŃŃ
на ĐżŃодНОМоннŃŃ
ŃпоŃиŃиŃĐľŃкиŃ
ĐşŃиŃĐľŃиŃŃ
ĐžŃвоŃĐ° на иППŃнОŃĐľŃапиŃ, вкНŃŃĐ°Ń Đ¸ĐźĐźŃнОНОгиŃĐľŃкиК Recist, иППŃннŃĐš Recist и иППŃнОПОдиŃиŃиŃОваннŃĐš RECIST
ĐŃниŃĐľŃкио Đ°ŃпокŃŃ Đ˝Đ°ŃНодŃŃвоннОгО Ńака ПОНОŃнОК МоНоСŃ
This study aimed to reveal the spectrum of BRca1 and BRca2 genes mutation in various ethnic groups of the Russian Federation. asystematic literature search includes data for the past 10 years and was conducted by using electronic databases of pubmed, eliBRaRY and ect.Material and methods. The review includes research data on the frequency of mutations of breast cancer-associated genes in various ethnic groups of the Russian Federation.Results. For ÂŤslavicÂť patients with a family history, the BRca1/2 mutation testing is the standard of care. in addition, the development of new antitumour drugs has resulted in improved survival rates. more than 1000 mutations of the BRca1 gene have been identified. Recent research is focused on the confirmation the beneficial effect of identified mutations. For the indigenous population (mongoloid ethnic groups), there are no standards for the treatment of inherited breast cancer. thus, the advances in molecular oncology for the treatment of hereditary breast cancer are not available for the indigenous population of the Russian Federation.Conclusion. In this context, the search for markers of early cancer detection and the development of criteria for therapy response are relevant for indigenous people. the development of new predictive and prognostic criteria of breast cancer among mongoloid ethnic groups with a family history will allow the innovative strategies for personalized molecular therapy to be developed.ĐŚĐľĐťŃ Đ¸ŃŃĐťĐľĐ´ĐžĐ˛Đ°Đ˝Đ¸Ń â ĐżŃОвоŃŃи ŃиŃŃоПаŃиŃĐľŃкиК анаНиС даннŃŃ
, иПоŃŃиŃ
ŃŃ Đ˛ ŃОвŃоПоннОК НиŃĐľŃĐ°ŃŃŃĐľ, Đž ŃпокŃŃĐľ ĐźŃŃĐ°ŃиК гонОв BRca1 и BRca2 в ŃаСНиŃĐ˝ŃŃ
ŃŃниŃĐľŃкиŃ
ĐłŃŃппаŃ
Đ ĐžŃŃиКŃкОК ФодоŃĐ°Ńии.ĐĐ°ŃĐľŃиаН и ПоŃОдŃ. Đ ĐžĐąĐˇĐžŃ Đ˛ĐşĐťŃŃĐľĐ˝Ń Đ´Đ°Đ˝Đ˝ŃĐľ иŃŃНодОваниК Đž ŃĐ°ŃŃĐžŃĐľ вŃŃŃĐľŃаоПОŃŃи ĐźŃŃĐ°ŃиК Đ ĐĐ-Đ°ŃŃĐžŃииŃОваннŃŃ
гонОв Ń ŃаСНиŃĐ˝ŃŃ
ŃŃниŃĐľŃкиŃ
ĐłŃŃпп Đ ĐžŃŃиКŃкОК ФодоŃĐ°Ńии, ОпŃйНикОваннŃĐľ Са пОŃНоднио 10 НоŃ. ĐОиŃĐş ĐżŃОиСвОдиНŃŃ Đ˛ ŃиŃŃоПаŃ
pubmed, eliBRaRYи Đ´Ń.РоСŃĐťŃŃĐ°ŃŃ. РнаŃŃĐžŃŃоо вŃĐľĐźŃ ŃĐľŃŃиŃОванио BRca1/2 ĐźŃŃĐ°ŃиК ŃвНŃĐľŃŃŃ ŃŃандаŃŃОП в НоŃонии наŃНодŃŃвоннОгО Đ ĐĐ Ń ÂŤŃНавŃĐ˝ŃкиŃ
Âť паŃионŃОв Ń ŃоПоКнОК иŃŃĐžŃиоК, Đ´ĐžŃŃигнŃŃ ĐżŃОгŃĐľŃŃ Đ˛ ŃаСŃайОŃко нОвŃŃ
ĐżŃĐžŃивООпŃŃ
ОНовŃŃ
ĐżŃопаŃĐ°ŃОв и СнаŃиŃоНŃĐ˝ŃĐš ŃĐžŃŃ ĐżĐžĐşĐ°ĐˇĐ°ŃоНоК вŃМиваоПОŃŃи, идонŃиŃиŃиŃОванО йОНоо 1000 ĐźŃŃĐ°ŃиК гона BRca1, ĐżŃОдОНМаоŃŃŃ ĐżĐžĐ¸ŃĐş паŃОгоннŃŃ
кНиниŃĐľŃки СнаŃиПŃŃ
ĐźŃŃĐ°ŃиК Đ´ĐťŃ Đ´Đ°Đ˝Đ˝ĐžĐš ĐłŃŃĐżĐżŃ ĐąĐžĐťŃĐ˝ŃŃ
. ĐднакО на даннŃĐš ĐźĐžĐźĐľĐ˝Ń ĐžŃŃŃŃŃŃвŃŃŃ ŃĐ˛ĐľĐ´ĐľĐ˝Đ¸Ń Đž ПОНокŃĐťŃŃĐ˝ŃŃ
ŃĐ°ĐşŃĐžŃĐ°Ń
, кОŃĐžŃŃĐľ ОйŃŃНОвНиваŃŃ ŃиŃĐş ŃаСвиŃĐ¸Ń Đ˝Đ°ŃНодŃŃвоннŃŃ
ŃĐžŃĐź Đ ĐĐ Đ´ĐťŃ ĐşĐžŃоннОгО наŃĐľĐťĐľĐ˝Đ¸Ń Đ ĐžŃŃиКŃкОК ФодоŃĐ°Ńии (ĐąŃŃŃŃŃ, Ńвонки, ŃĐşŃŃŃ, Đ°ĐťŃĐ°ĐšŃŃ, ŃŃвинŃŃ, Ń
акаŃŃ Đ¸ Đ´Ń.). ТакиП ОйŃаСОП, ŃОвŃоПоннŃĐľ Đ´ĐžŃŃĐ¸ĐśĐľĐ˝Đ¸Ń ĐźĐžĐťĐľĐşŃĐťŃŃнОК ОнкОНОгии в НоŃонии наŃНодŃŃвоннŃŃ
ŃĐžŃĐź Đ ĐРно Đ´ĐžŃŃŃĐżĐ˝Ń Đ´ĐťŃ ĐşĐžŃоннОгО наŃĐľĐťĐľĐ˝Đ¸Ń Đ ĐžŃŃиКŃкОК ФодоŃĐ°Ńии.ĐакНŃŃонио. ĐŃодŃŃавНоннŃĐľ даннŃĐľ пОдŃвоŃМдаŃŃ Đ°ĐşŃŃĐ°ĐťŃнОŃŃŃ ĐżĐžĐ¸Ńка ПаŃкоŃОв ŃанноК диагнОŃŃики, ŃŃŃокŃивнОŃŃи ŃĐľŃапии, ŃиŃка ĐżŃОгŃĐľŃŃиŃĐžĐ˛Đ°Đ˝Đ¸Ń Đ ĐĐ Ń ĐşĐžŃоннŃŃ
ŃŃнОŃОв. ĐаннŃĐľ Đž ПОНокŃĐťŃŃĐ˝ŃŃ
ПоŃ
аниСПаŃ
наŃНодŃŃвоннОгО Đ ĐĐ Ń ŃŃниŃĐľŃкиŃ
ĐłŃŃпп Ń ŃоПоКнОК иŃŃĐžŃиоК, ĐżŃинадНоМаŃиŃ
Đş ПОнгОНОиднОК ŃĐ°ŃĐľ, пОСвОНŃŃ Đ˛ поŃŃпокŃиво ŃаСŃайОŃĐ°ŃŃ Đ¸Đ˝Đ˝ĐžĐ˛Đ°ŃиОннŃĐľ ŃŃŃĐ°Ńогии поŃŃОнаНиСиŃОваннОК ПОНокŃĐťŃŃнОК ŃĐľŃапии
ĐĐžĐ˛Đ°Ń ĐźŃŃĐ°ŃĐ¸Ń Đ˛ гоно PALB2, Đ°ŃŃĐžŃииŃĐžĐ˛Đ°Đ˝Đ˝Đ°Ń Ń Đ˝Đ°ŃНодŃŃвоннŃĐź ŃакОП ПОНОŃнОК ĐśĐľĐťĐľĐˇŃ Ń ĐźĐžĐťĐžĐ´ĐžĐš паŃионŃки, ĐżŃинадНоМаŃоК Đş ŃĐşŃŃŃкОК ŃŃниŃĐľŃкОК ĐłŃŃппо
Background. Breast cancer (BC) is the most common female malignancy worldwide. Partner And Localizer of BRCA2 gene (PALB2) is directly involved in DNA damage response. Germline mutation in PALB2 has been identified in breast cancer and familial pancreatic cancer cases, accounting for approximately 1â2% and 3â4%, respectively. The goal of this report was to describe new PALB2 mutation in a young Yakut breast cancer patient with family history of cancer. Material and Methods. Genomic DNA were isolated from blood samples and used to prepare libraries using a capture-based target enrichment kit, Hereditary Cancer Solution⢠(SOP HiA GE NETICS , Switzerland), covering 27 genes (ATM, APC, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FAM175A, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, PMS2CL, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53 and XRCC2). Paired-end sequencing (2 Ă 150 bp) was conducted using NextSeq 500 system (Illumina, USA ). Results. Here we describe a case of a never-before-reported mutation in the PALB2 gene that led to the early onset breast cancer. We report the case of a 39-year-old breast cancer Yakut woman with a family history of pancreatic cancer. Bioinformatics analysis of the NGS data revealed the presence of the new PALB2 gene germinal frameshift deletion (NM_024675:exon1:c.47delA:p.K16fs). In accordance with dbPubMed ClinVar, new mutation is located in codon of the PALB2 gene, where the likely pathogenic donor splice site mutation (NM_024675.3:c.48+1delG) associated with hereditary cancer-predisposing syndrome has been earlier described. Conclusion. We found a new never-before-reported mutation in PALB2 gene, which probably associated with early onset breast cancer in Yakut indigenous women with a family history of pancreatic cancer.ĐĐşŃŃĐ°ĐťŃнОŃŃŃ. Đ Đ°Đş ПОНОŃнОК ĐśĐľĐťĐľĐˇŃ ĐˇĐ°Đ˝Đ¸ĐźĐ°ĐľŃ ĐťĐ¸Đ´Đ¸ŃŃŃŃио пОСиŃии пО ŃŃĐžĐ˛Đ˝Ń ĐˇĐ°ĐąĐžĐťĐľĐ˛Đ°ĐľĐźĐžŃŃи вО вŃоП ПиŃĐľ. Đон ОнкОŃŃĐżŃĐľŃŃĐžŃ PALB2 наŃŃĐ´Ń Ń ŃакиПи гонаПи, как BRCA1, BRCA2, вОвНоŃон в ĐżŃĐžŃĐľŃŃŃ ŃопаŃĐ°Ńии пОвŃоМдоннОК ĐĐĐ. ЧаŃŃĐžŃĐ° вŃŃŃĐľŃаоПОŃŃи гоŃПинаНŃĐ˝ŃŃ
ĐźŃŃĐ°ŃиК гона PALB2 ĐżŃи Ńако ПОНОŃнОК ĐśĐľĐťĐľĐˇŃ Đ¸ ŃоПоКнŃŃ
ŃĐťŃŃĐ°ŃŃ
Ńака пОдМоНŃĐ´ĐžŃнОК ĐśĐľĐťĐľĐˇŃ ŃĐžŃŃавНŃĐľŃ ĐżŃийНиСиŃоНŃнО 1â2 % и 3â4 % ŃООŃвоŃŃŃвоннО. ĐŃодŃŃавНон кНиниŃĐľŃкиК ŃĐťŃŃĐ°Đš 39-НоŃноК МонŃинŃ, ĐżŃинадНоМаŃоК Đş ŃĐşŃŃŃкОК ŃŃниŃĐľŃкОК ĐłŃŃппо, Ń Đ´Đ¸Đ°ĐłĐ˝ĐžĐˇĐžĐź ŃĐ°Đş ПОНОŃнОК ĐśĐľĐťĐľĐˇŃ Ń ŃоПоКнОК иŃŃĐžŃиоК Ńака пОдМоНŃĐ´ĐžŃнОК МоНоСŃ. ĐĐ°ŃĐľŃиаН и ПоŃОдŃ. ĐĐľĐ˝ĐžĐźĐ˝Đ°Ń ĐĐРвŃдоНона иС поŃиŃĐľŃиŃĐľŃкОК ĐşŃОви, ĐĐĐ-йийНиОŃоки ĐżŃигОŃавНиваНи Ń Đ¸ŃпОНŃСОваниоП найОŃĐ° Hereditary Cancer Solution⢠(Sophia Genetics, ШвоКŃĐ°ŃиŃ) Đ´ĐťŃ Đ¸ĐˇŃŃĐľĐ˝Đ¸Ń ŃŃĐ°ŃŃŃĐ° 27 гонОв (ATM, APC, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, FAM175A, MLH1, MRE11A, MSH2, MSH6, MUTYH, NBN, PALB2, PIK3CA, PMS2, PMS2CL, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53 и XRCC2). ХоквониŃОванио (2 Ă 150 Đż.Đ˝.) ĐżŃОвОдиНОŃŃ Ń Đ¸ŃпОНŃСОваниоП ŃиŃŃĐľĐźŃ NextSeq 500 (Illumina, ХШĐ). РоСŃĐťŃŃĐ°ŃŃ. ĐĐž ŃоСŃĐťŃŃĐ°ŃĐ°Đź йиОинŃĐžŃПаŃиŃĐľŃкОгО анаНиСа даннŃŃ
NGS Ń 39-НоŃноК МонŃинŃ, ĐżŃинадНоМаŃоК Đş ŃĐşŃŃŃкОК ŃŃниŃĐľŃкОК ĐłŃŃппо, Ń Đ´Đ¸Đ°ĐłĐ˝ĐžĐˇĐžĐź ŃĐ°Đş ПОНОŃнОК ĐśĐľĐťĐľĐˇŃ Ń ŃоПоКнОК иŃŃĐžŃиоК Ńака пОдМоНŃĐ´ĐžŃнОК ĐśĐľĐťĐľĐˇŃ ĐžĐąĐ˝Đ°ŃŃМона Đ˝ĐžĐ˛Đ°Ń ĐłĐľŃПинаНŃĐ˝Đ°Ń ĐźŃŃĐ°ŃĐ¸Ń ĐłĐľĐ˝Đ° PALB2 ŃĐž ŃдвигОП ŃаПки ŃŃиŃŃĐ˛Đ°Đ˝Đ¸Ń (NM_024675: Exon1: c.47delA: p.K16FS). Đ ŃООŃвоŃŃŃвии Ń dbPubmed ClinVar Đ˝ĐžĐ˛Đ°Ń ĐźŃŃĐ°ŃĐ¸Ń ĐłĐľĐ˝Đ° PALB2 ŃĐ°ŃпОНОМона в ŃОП Мо кОдОно, гдо Ńаноо ĐąŃНа ОпиŃана, воŃĐžŃŃнО паŃОгоннаŃ, ĐźŃŃĐ°ŃĐ¸Ń ŃĐ°ĐšŃĐ° ŃпНаКŃинга (NM_024675.3: Exon1: c.48+1delG), вОвНоŃĐľĐ˝Đ˝Đ°Ń Đ˛ паŃОгоноС наŃНодŃŃвоннŃŃ
ŃĐžŃĐź Ńака ПОНОŃнОК ĐśĐľĐťĐľĐˇŃ Đ¸ ŃиŃника. ĐакНŃŃонио. ĐпоŃвŃĐľ Ń 39-НоŃноК МонŃинŃ, ĐżŃинадНоМаŃоК Đş ŃĐşŃŃŃкОК ŃŃниŃĐľŃкОК ĐłŃŃппо, Ń Đ´Đ¸Đ°ĐłĐ˝ĐžĐˇĐžĐź ŃĐ°Đş ПОНОŃнОК ĐśĐľĐťĐľĐˇŃ Đ¸ Ń ŃоПоКнОК иŃŃĐžŃиоК Ńака пОдМоНŃĐ´ĐžŃнОК ĐśĐľĐťĐľĐˇŃ ĐžĐąĐ˝Đ°ŃŃМона нОваŃ, воŃĐžŃŃнО паŃОгоннаŃ, гоŃПинаНŃĐ˝Đ°Ń ĐźŃŃĐ°ŃĐ¸Ń ĐłĐľĐ˝Đ° PALB2 ŃĐž ŃдвигОП ŃаПки ŃŃиŃŃĐ˛Đ°Đ˝Đ¸Ń (NM_024675: Exon1: c.47delA: p.K16FS)
ĐĐ°ŃиайоНŃнОŃŃŃ ĐźĐ¸ŃĐžŃ ĐžĐ˝Đ´ŃиаНŃнОгО гонОПа Ń ĐąĐžĐťŃĐ˝ŃŃ ŃакОП ПОНОŃнОК ĐśĐľĐťĐľĐˇŃ Đ˛ пОпŃĐťŃŃии ŃĐşŃŃОк
Background. The Sakha (Yakutia) population, the indigenous population of Siberia living in Yakutia, has one of the lowest rates of breast cancer (BC) incidence worldwide. The low BC incidence among the indigenous population of Yakutia has been reported by several authors, but to date the reasons for this phenomenon have not been fully elucidated. It should be noted that the study of factors that reduce the risk of BC is important for its prevention. In several studies, no hereditary BC was found in the Yakuts, and no pathogenic variants of the BRCA1/2 genes associated with hereditary syndromes of breast and ovarian cancers were found. In this regard, we decided to shift the focus to studying the mitochondrial genome of Sakha BC patients using the sequencing method.The purpose of the study was to identify BC-associated mitochondrial genome variants in Sakha patients.Material and Methods. The study included 14 Sakha patients diagnosed with BC. The median age of the patients was 49 years. DNA isolation was performed using phenol-chloroform extraction. DNA libraries were prepared using the Nextera Flex kit (Illumina, USA).Whole-genome sequencing of the mitochondrial genome was performed on a MiSeq instrument (IlluminĐ°, USA). in the Shared Use Centre of the Research Institute of Medical Genetics, Tomsk National Research Centre of the Russian Academy of Sciences. The results obtained in BC patients were compared with those of control subjects.Results. In Sakha women with BC, 159 mitochondrial genome variants that differed from the human mitochondrial DNA (mtDNA) reference sequence (rCRS) were identified. Likely pathogenic variants m.3736G>A of the MT-ND1 gene and m.7279T>C of the MT-CO1 gene were shown to be associated with BC. For the first time, variants predisposing to BC (m.10398A>G; m.14783T>C; m.15043G>A; m.15301G>A) were identified. A distinctive feature of the mitochondrial genome of populations with a low BC incidence is a high level of mtDNA variants with changes in the length of the polycytosine region in the D310 locus.Conclusion. For the first time, mtDNA variants with changes in the length of the polycytosine tract in the D310 locus and likely pathogenic variants m.3736G>A of the MT-ND1 gene and m.7279T>C of the MT-CO1 gene were identified in Sakha BC women. The data obtained indicate that further studies on the role of the identified mtDNA variants in the development of BC using a larger sample of Sakha patients are required.Đводонио. ĐОпŃĐťŃŃĐ¸Ń ŃĐ°Ń
Đ° (ŃĐşŃŃŃ) â кОŃоннОо наŃоНонио ХийиŃи, ĐżŃОМиваŃŃоо на ŃĐľŃŃиŃĐžŃии ĐŻĐşŃŃии, ĐžŃНиŃĐ°ĐľŃŃŃ ĐžĐ´Đ˝Đ¸Đź иС ŃĐ°ĐźŃŃ
ниСкиŃ
в ПиŃĐľ ŃŃОвноП СайОНоваоПОŃŃи ŃакОП ПОНОŃнОК ĐśĐľĐťĐľĐˇŃ (Đ ĐĐ). ĐиСкиК ŃŃĐžĐ˛ĐľĐ˝Ń ĐˇĐ°ĐąĐžĐťĐľĐ˛Đ°ĐľĐźĐžŃŃи Đ ĐРкОŃоннОгО наŃĐľĐťĐľĐ˝Đ¸Ń ĐŻĐşŃŃии ĐžŃПоŃон в ŃŃĐ´Đľ ĐżŃйНикаŃиК, нО Đ´Đž наŃŃĐžŃŃогО вŃоПони ĐżŃиŃĐ¸Đ˝Ń ŃŃОгО ŃĐ˛ĐťĐľĐ˝Đ¸Ń Đ˝Đľ Đ´Đž кОнŃĐ° вŃŃŃнонŃ. ХНодŃĐľŃ ĐžŃПоŃиŃŃ, ŃŃĐž иСŃŃонио ŃĐ°ĐşŃĐžŃОв, ŃниМаŃŃиŃ
ŃиŃĐş ĐˇĐ°ĐąĐžĐťĐľĐ˛Đ°Đ˝Đ¸Ń Đ ĐĐ, Đ¸ĐźĐľĐľŃ Đ˛Đ°ĐśĐ˝ĐžĐľ СнаŃонио Đ´ĐťŃ ĐľĐłĐž ĐżŃĐžŃиНакŃики. ĐĐž ŃоСŃĐťŃŃĐ°ŃĐ°Đź ŃŃĐ´Đ° иŃŃНодОваниК, Ń ŃĐşŃŃОв но ОйнаŃŃМонО наŃНодŃŃвоннŃŃ
ŃĐžŃĐź Đ ĐĐ, но наКдонО паŃОгоннŃŃ
ваŃианŃОв гонОв BRCA1/2, Đ°ŃŃĐžŃииŃОваннŃŃ
Ń Đ˝Đ°ŃНодŃŃвоннŃПи ŃиндŃОПаПи Đ ĐРи Ńака ŃиŃника (Đ ĐŻ). Đ ŃвŃСи Ń ŃŃиП ĐźŃ ĐżŃинŃНи ŃĐľŃонио ŃПоŃŃиŃŃ Đ°ĐşŃĐľĐ˝Ń Đ˝Đ° иŃŃНодОванио ПиŃĐžŃ
ОндŃиаНŃнОгО гонОПа йОНŃĐ˝ŃŃ
Đ ĐĐ ŃĐ°Ń
Đ° ПоŃОдОП ŃоквониŃОваниŃ.ĐŚĐľĐťŃ Đ¸ŃŃĐťĐľĐ´ĐžĐ˛Đ°Đ˝Đ¸Ń â вŃŃвиŃŃ Đ˛Đ°ŃианŃŃ ĐźĐ¸ŃĐžŃ
ОндŃиаНŃнОгО гонОПа, Đ°ŃŃĐžŃииŃОваннŃĐľ Ń Đ ĐĐ, Ń ĐżĐ°ŃионŃОк ŃĐ°Ń
Đ°.ĐĐ°ŃĐľŃиаН и ПоŃОдŃ. РиŃŃНодОванио вкНŃŃонО 14 паŃионŃОк ŃĐ°Ń
Đ° Ń Đ´Đ¸Đ°ĐłĐ˝ĐžĐˇĐžĐź Đ ĐĐ, ŃŃодниК вОСŃĐ°ŃŃ ŃĐžŃŃавиН 49 НоŃ. ĐŃдоНонио ĐĐĐ ĐžŃŃŃĐľŃŃвНŃНи ПоŃОдОП ŃонОН-Ń
НОŃĐžŃĐžŃПнОК ŃĐşŃŃŃĐ°ĐşŃии. ĐĐĐ-йийНиОŃоки гОŃОвиНи Ń ĐżĐžĐźĐžŃŃŃ Đ˝Đ°ĐąĐžŃĐ° Nextera Flex (Illumina, ХШĐ). ĐОНнОгонОПнОо ŃоквониŃОванио ПиŃĐžŃ
ОндŃиаНŃнОгО гонОПа вŃпОНнŃНОŃŃ Đ˝Đ° ĐżŃийОŃĐľ MiSeq (Illumina, ХШĐ) на йаСо ĐŚĐРТОПŃкОгО ĐĐĐĐŚ. ĐОНŃŃоннŃĐľ ŃоСŃĐťŃŃĐ°ŃŃ Ń ĐąĐžĐťŃĐ˝ŃŃ
Đ ĐĐ ŃŃавниваНиŃŃ Ń ĐżĐžĐżŃĐťŃŃиОннŃĐź кОнŃŃОНоП.РоСŃĐťŃŃĐ°ŃŃ. ĐŁ МонŃин ŃĐ°Ń
Đ°, йОНŃĐ˝ŃŃ
Đ ĐĐ, вŃŃвНонО 159 ваŃианŃОв ПиŃĐžŃ
ОндŃиаНŃнОгО гонОПа, ĐžŃНиŃĐ°ŃŃиŃ
ŃŃ ĐžŃ ŃĐľŃĐľŃонŃнОК пОŃНодОваŃоНŃнОŃŃŃŃ ĐźĐ¸ŃĐžŃ
ОндŃиаНŃнОК ĐĐĐ (ĐźŃĐĐĐ) ŃоНОвока (rCRS). ĐОкаСана Đ°ŃŃĐžŃиаŃĐ¸Ń Đ˛ĐľŃĐžŃŃнО паŃОгоннŃŃ
ваŃианŃОв m.3736G>A гона ĐТ-ND1 и m.7279T>C гона MT-CO1 Ń Đ ĐĐ. ĐпоŃвŃĐľ вŃŃĐ˛ĐťĐľĐ˝Ń Đ˛Đ°ŃианŃŃ, ĐżŃодŃĐ°ŃпОНагаŃŃио Đş Đ ĐĐ (m.10398A>G; m.14783T>C; m.15043G>A; m.15301G>A). ĐŃОйоннОŃŃŃŃ ĐźĐ¸ŃĐžŃ
ОндŃиаНŃнОгО гонОПа пОпŃĐťŃŃиК Ń Đ˝Đ¸ĐˇĐşĐ¸Đź ŃŃОвноП СайОНоваоПОŃŃи Đ ĐĐ ŃвНŃĐľŃŃŃ Đ˛ŃŃОкиК ŃŃĐžĐ˛ĐľĐ˝Ń Đ˛Đ°ŃианŃОв ĐźŃĐĐĐ Ń Đ¸ĐˇĐźĐľĐ˝ĐľĐ˝Đ¸ĐľĐź Đ´ĐťĐ¸Đ˝Ń ĐżĐžĐťĐ¸ŃиŃОСинОвОгО ŃŃĐ°ŃŃка в НОкŃŃĐľ D310.ĐакНŃŃонио. ĐпоŃвŃĐľ Ń ĐśĐľĐ˝Ńин Ń Đ ĐРиС пОпŃĐťŃŃии ŃĐ°Ń
Đ° вŃŃĐ˛ĐťĐľĐ˝Ń Đ˛Đ°ŃианŃŃ ĐźŃĐĐĐ Ń Đ¸ĐˇĐźĐľĐ˝ĐľĐ˝Đ¸ĐľĐź Đ´ĐťĐ¸Đ˝Ń ĐżĐžĐťĐ¸ŃиŃОСинОвОгО ŃŃĐ°ĐşŃĐ° в НОкŃŃĐľ D310 и воŃĐžŃŃнО паŃОгоннŃĐľ ваŃианŃŃ m.3736G>A гона ĐТ-ND1 и m.7279T>C гона MT-CO1. ĐОНŃŃоннŃĐľ даннŃĐľ ŃвидоŃоНŃŃŃвŃŃŃ Đž ŃоНоŃООйŃаСнОŃŃи Đ´Đ°ĐťŃноКŃогО иСŃŃĐľĐ˝Đ¸Ń ŃОНи вŃŃвНоннŃŃ
ваŃианŃОв ĐźŃĐĐРв ŃаСвиŃии Đ ĐРна ŃĐ°ŃŃиŃоннОК вŃйОŃко паŃионŃОв ŃĐ°Ń
Đ°
Use of anticoagulants and antiplatelet agents in stable outpatients with coronary artery disease and atrial fibrillation. International CLARIFY registry
Track E Implementation Science, Health Systems and Economics
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138412/1/jia218443.pd